Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis

Arthritis and Rheumatism

Volumn 62, Issue 11, 2010, Pages 3467-3476

  Marquart, Sieglinde ^a   Zerr, Pawel ^a   Akhmetshina, Alfiya ^a   Palumbo, Katrin ^a   Reich, Nicole ^a   Tomcik, Michal ^a   Horn, Angelika ^a   Dees, Clara ^a   Engel, Matthias ^a   Zwerina, Jochen ^a   Distler, Oliver ^b   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CANNABINOID 1 RECEPTOR; HYDROXYPROLINE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; IN VIVO STUDY; LEUKOCYTE; MALE; MESENCHYME CELL; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SKINFOLD; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; WILD TYPE;

ANIMALS; BONE MARROW TRANSPLANTATION; FIBROSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; RECEPTOR, CANNABINOID, CB1; SCLERODERMA, SYSTEMIC; STATISTICS, NONPARAMETRIC;

EID: 78249233276     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27642     Document Type: Article

References (39)

1. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989 - 2003.
2. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557 - 67.
3. Kahari VM, Sandberg M, Kalimo H, Vuorio T, Vuorio E,. Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 1988; 90: 664 - 70.
4. Mackie K,. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008; 20 Suppl 1: 10 - 4.
5. Bisogno T,. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol 2008; 20 Suppl 1: 1 - 9.
6. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H,. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008; 68: 339 - 42.
7. Bab I, Zimmer A,. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol 2008; 153: 182 - 8.
8. Klein TW,. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400 - 11.
9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI,. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561 - 4.
10. Munro S, Thomas KL, Abu-Shaar M,. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61 - 5.
11. Idris AI, van 't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005; 11: 774 - 9.
12. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 2006; 103: 696 - 701.
13. Bifulco M, Santoro A, Laezza C, Malfitano AM,. Cannabinoid receptor CB1 antagonists state of the art and challenges. Vitam Horm 2009; 81: 159 - 89.
14. Scheen AJ, Paquot N,. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Pract Res Clin Endocrinol Metab 2009; 23: 103 - 16.
15. Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009; 60: 1129 - 36.
16. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530 - 4.
17. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311 - 22.
18. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 1999; 289: 1427 - 33.
19. Luszczki JJ, Czuczwar P, Cioczek-Czuczwar A, Czuczwar SJ,. Arachidonyl-2-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 2006; 547: 65 - 74.
20. Green MC, Sweet HO, Bunker LE,. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976; 82: 493 - 512.
21. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008; 22: 2214 - 22.
22. Woessner JF Jr., The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440 - 7.
23. Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zerr P, et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2010; 62: 280 - 90.
24. Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008; 58: 1475 - 84.
25. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219 - 24.
26. Chung L, Krishnan E, Chakravarty EF,. Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. Rheumatology (Oxford) 2007; 46: 1808 - 13.
27. Charles C, Clements P, Furst DE,. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006; 367: 1683 - 91.
28. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006; 12: 671 - 6.
29. Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58: 2854 - 65.
30. Maurer B, Busch N, Jungel A, Pileckyte M, Gay RE, Michel BA, et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009; 120: 2367 - 76.
31. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128: 742 - 55.
32. Michalski CW, Maier M, Erkan M, Sauliunaite D, Bergmann F, Pacher P, et al. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS ONE 2008; 3: e1701.
33. Klein TW, Newton CA,. Therapeutic potential of cannabinoid-based drugs. Adv Exp Med Biol 2007; 601: 395 - 413.
34. Distler JH, Akhmetshina A, Schett G, Distler O,. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48: 98 - 103 [review].
35. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001; 44: 2665 - 78.
36. Garcia-Gonzalez E, Selvi E, Balistreri E, Lorenzini S, Maggio R, Natale MR, et al. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology (Oxford) 2009; 48: 1050 - 6.
37. Klein TW, Newton C, Larsen K, Chou J, Perkins I, Lu L, et al. Cannabinoid receptors and T helper cells. J Neuroimmunol 2004; 147: 91 - 4.
38. Distler JH, Jungel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006; 54: 214 - 25.
39. Wynn TA,. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583 - 94.